S. Agarwal, A. M. Hartz, W. F. Elmquist, and B. Bauer, Breast cancer resistance protein and P-glycoprotein in brain cancer: two gatekeepers team up, Curr. Pharm. Des, vol.17, pp.2793-2802, 2011.

S. Agarwala, W. Chen, and T. J. Cook, Effect of chlorpyrifos on efflux transporter gene expression and function in caco-2 cells, Toxicol. Vitr, vol.18, pp.403-409, 2004.

L. M. Aleksunes, R. L. Yeager, X. Wen, J. Y. Cui, and C. D. Klaassen, Repression of hepatobiliary transporters and differential regulation of classic and alternative bile acid pathways in mice during pregnancy, Toxicol. Sci, vol.130, pp.257-268, 2012.

M. Alriquet, K. Sevin, A. Gaborit, P. Comby, B. Ruty et al., Characterization of SLC transporters in human skin, ADMET DMPK, vol.3, pp.34-44, 2015.

D. E. Amacher, The regulation of human hepatic drug transporter expression by activation of xenobiotic-sensing nuclear receptors, Expert Opin. Drug Metab. Toxicol, vol.12, pp.1463-1477, 2016.

G. L. Amidon, H. Lennernäs, V. P. Shah, and J. R. Crison, A Theoretical Basis for a Biopharmaceutic Drug. The Correlation of in Vitro Drug Product Dissolution and in Vivo Bioavailability, Pharm. Res, 1995.

V. Andersen, M. Østergaard, J. Christensen, K. Overvad, A. Tjønneland et al., Polymorphisms in the xenobiotic transporter Multidrug Resistance 1 (MDR1) and interaction with meat intake in relation to risk of colorectal cancer in a Danish prospective case-cohort study, BMC Cancer, vol.9, 2009.

A. Angelini, L. Centurione, S. Sancilio, M. L. Castellani, P. Conti et al., The effect of the plasticizer diethylhexyl phthalate on transport activity and expression of P-glycoprotein in parental and doxo-resistant human sarcoma cell lines, J. Biol. Regul. Homeost. Agents, vol.25, pp.203-211, 2011.

L. Bain and G. Leblanc, Interaction of structurally diverse pesticides with the human MDR1 gene product P-glycoprotein, Toxicol. Appl. Pharmacol, vol.141, pp.288-298, 1996.

L. Z. Benet, The role of BCS (biopharmaceutics classification system) and BDDCS (biopharmaceutics drug disposition classification system) in drug development, J. Pharm. Sci, vol.102, pp.34-42, 2013.

E. A. Benson, M. T. Eadon, Z. Desta, Y. Liu, H. Lin et al., Rifampin regulation of drug transporters gene expression and the association of microRNAs in human hepatocytes, Front. Pharmacol, vol.7, pp.1-13, 2016.

J. Bentz, M. P. Connor, D. Bednarczyk, J. Coleman, C. Lee et al., Variability in P-glycoprotein inhibitory potency (IC 50) using various in vitro experimental systems: implications for universal digoxin drug-drug interaction risk assessment decision criteria s, Drug Metab. Dispos, vol.41, pp.1347-1366, 2013.

J. Bessems, G. Loizou, K. Krishnan, H. Clewell, C. Bernasconi et al., PBTK modelling platforms and parameter estimation tools to enable animal-free risk assessment. Recommendations from a joint EPAA -EURL ECVAM ADME workshop, Regul. Toxicol. Pharmacol, vol.68, pp.119-139, 2014.
URL : https://hal.archives-ouvertes.fr/ineris-01855482

J. Bessems, S. Coecke, V. Gouliarmou, M. Whelan, and A. Worth, EURL ECVAM strategy for achieving 3Rs impact in the assessment of toxicokinetics and systemic toxicity, JRC Sci. Policy Reports, 2015.

C. Bosquillon, Drug transporters in the lung-do they play a role in the biopharmaceutics of inhaled drugs?, J. Pharm. Sci, vol.99, pp.2240-2255, 2010.

F. Broccatelli, C. A. Larregieu, G. Cruciani, T. I. Oprea, and L. Z. Benet, Improving the prediction of the brain disposition for orally administered drugs using BDDCS, Adv. Drug Deliv. Rev, vol.64, pp.95-109, 2012.

K. L. Brouwer, D. Keppler, K. A. Hoffmaster, D. A. Bow, Y. Cheng et al., In vitro methods to support transporter evaluation in drug discovery and development, Clin. Pharmacol. Ther, vol.94, pp.95-112, 2013.

A. Bruyere, C. Hubert, M. L. Chedik, K. Sayyed, B. Stieger et al., Inhibition of SLC drug transporter activities by environmental bisphenols, Toxicol. Vitr, vol.40, pp.34-44, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01467545

S. Bucher, M. Le-vee, E. Jouan, and O. Fardel, Regulation of hepatic drug transporter activity and expression by organochlorine pesticides, J. Biochem. Mol. Toxicol, vol.28, pp.119-128, 2014.
URL : https://hal.archives-ouvertes.fr/hal-01063656

H. Burger, H. Van-tol, A. W. Boersma, E. A. Wiemer, G. Stoter et al., Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump, Blood, vol.104, pp.2940-2943, 2004.

G. Camenisch, J. Riede, A. Kunze, J. Huwyler, B. Poller et al., The extended clearance model and its use for the interpretation of hepatobiliary elimination data, ADMET DMPK, vol.3, pp.1-14, 2015.

S. Casati, A. Worth, P. Amcoff, and M. Whelan, EURL ECVAM strategy for replacement of animal testing for skin sensitisation Hazard identification and classification, JRC Sci. Policy Reports, 2013.

L. Chedik, A. Bruyere, A. Bacle, S. Potin, M. Le-vée et al., Interactions of pesticides with membrane drug transporters: implications for toxicokinetics and toxicity, Expert Opin. Drug Metab. Toxicol, vol.14, pp.739-752, 2018.
URL : https://hal.archives-ouvertes.fr/hal-01863032

L. Chedik, A. Bruyere, and O. Fardel, Interactions of organophosphorus pesticides with solute carrier (SLC) drug transporters. Xenobiotica 1-12, 2018.
URL : https://hal.archives-ouvertes.fr/hal-01863798

Y. Chen, S. Zhang, M. Sorani, and K. M. Giacomini, Transport of Paraquat by human organic cation transporters and multidrug and toxic compound extrusion family, J. Pharmacol. Exp. Ther, vol.322, pp.695-700, 2007.

X. Chu, M. Liao, H. Shen, K. Yoshida, A. A. Zur et al., Clinical probes and endogenous biomarkers as substrates for transporter drug-drug interaction evaluation: perspectives from the international transporter consortium, Consortium, on behalf of the I.T, vol.104, pp.836-864, 2018.

L. Clerbaux, S. Coecke, A. Lumen, T. Kliment, A. P. Worth et al., Capturing the applicability of in vitro-in silico membrane transporter data in chemical risk assessment and biomedical research, Sci. Total Environ, vol.645, pp.97-108, 2018.

S. Coecke, O. Pelkonen, S. B. Leite, U. Bernauer, J. G. Bessems et al., Toxicokinetics as a key to the integrated toxicity risk assessment based primarily on non-animal approaches, Toxicol. Vitr, vol.27, pp.1570-1577, 2013.
URL : https://hal.archives-ouvertes.fr/ineris-00963488

R. Corvi, F. Madia, A. Worth, and M. Whelan, EURL ECVAM strategy to avoid and reduce animal use in genotoxicity testing, JRC Sci. Policy Reports, 2013.

L. Couture, J. A. Nash, and J. Turgeon, The ATP-binding cassette transporters and their implication in drug disposition: a special look at the heart, Pharmacol. Rev, vol.58, pp.244-258, 2006.

L. C. Czuba, K. M. Hillgren, and P. W. Swaan, Post-translational modifications of transporters, Pharmacol. Ther, vol.192, pp.88-99, 2018.

A. Daina, O. Michielin, and V. Zoete, SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules, Sci. Rep, vol.7, pp.1-13, 2017.

M. L. Danielson, G. A. Sawada, T. J. Raub, and P. Desai, In silico and in vitro assessment of OATP1B1 inhibition in drug discovery, Mol. Pharm, vol.15, pp.3060-3068, 2018.

T. De-bruyn, B. Stieger, P. F. Augustijns, and P. P. Annaert, Clearance prediction of HIV protease inhibitors in man: role of hepatic uptake, J. Pharm. Sci, vol.105, pp.854-863, 2016.

N. A. Devries, J. Zhao, E. Kroon, T. Buckle, J. H. Beijnen et al., Cancer therapy: preclinical P-glycoprotein and breast cancer resistance protein: two dominant transporters working together in limiting the brain penetration of topotecan, Clin. Cancer Res, vol.1, pp.6440-6450, 2007.

B. Döring and E. Petzinger, Phase 0 and phase III transport in various organs: combined concept of phases in xenobiotic transport and metabolism, Drug Metab. Rev, vol.46, pp.261-282, 2014.

S. Durmus, S. Van-hoppe, and A. H. Schinkel, The impact of organic anion-transporting polypeptides (OATPs) on disposition and toxicity of antitumor drugs: insights from knockout and humanized mice, Drug Resist. Updat, vol.27, pp.72-88, 2016.

, European Chemicals Agency. The Use of Alternatives to Testing on Animals for the REACH RegulationThe Use of Alternatives to Testing on Animals for the REACH Regulation, ECHA, 2014.

, European Food Safety Authority. Modern methodologies and tools for human hazard assessment of chemicals, EFSA J, vol.12, 2014.

A. Ehlers, A. These, S. Hessel, A. Preiss-weigert, and A. Lampen, Active elimination of the marine biotoxin okadaic acid by P-glycoprotein through an in vitro gastrointestinal barrier, Toxicol. Lett, vol.225, pp.311-317, 2014.

S. Ekins, The next era: deep learning in pharmaceutical research, Pharm. Res, vol.33, pp.2594-2603, 2016.

, Guideline on the investigation of drug interactions Discussion), European Medicines Agency, 2012.

K. Engström, T. M. Love, G. E. Watson, G. Zareba, A. Yeates et al., Polymorphisms in ATP-binding cassette transporters associated with maternal methylmercury disposition and infant neurodevelopment in mother-infant pairs in the Seychelles Child Development Study, Environ. Int, vol.94, pp.224-229, 2016.

D. Epel, T. Luckenbach, C. N. Stevenson, L. A. Macmanus-spencer, A. Hamdoun et al., Efflux transporters: newly appreciated roles in protection against pollutants, Environ. Sci. Technol, vol.42, pp.3914-3920, 2008.

P. W. Fan, Y. Song, L. M. Berezhkovskiy, J. Cheong, E. G. Plise et al., Practical permeability-based hepatic clearance classification system (HepCCS) in drug discovery, Future Med. Chem, vol.6, 1995.

O. Fardel, E. Kolasa, and M. Le-vee, Environmental chemicals as substrates, inhibitors or inducers of drug transporters: implication for toxicokinetics, toxicity and pharmacokinetics, Expert Opin. Drug Metab. Toxicol, vol.8, pp.29-46, 2012.
URL : https://hal.archives-ouvertes.fr/inserm-00872876

, Guidance for Industry: Drug Interaction Studies -Study design, Data analysis, FDA, 2012.

. Fda, US Food and Drug Administration, Vitro Metabolism-and Transporter-Mediated Drug-Drug Interaction Studies

, Guidance for Industry: Waiver of in vivo bioavailability and bioequivalence studies for immediate release solid oral dosage forms based on a biopharmaceutics classification system, FDA, 2017.

, Draft Guidance for Industry: Physiologically Based Pharmacokinetic Analyses -Format and Content Guidance for Industry, FDA, 2018.

W. J. Fischer, S. Altheimer, V. Cattori, P. J. Meier, D. R. Dietrich et al., Organic anion transporting polypeptides expressed in liver and brain mediate uptake of microcystin, Toxicol. Appl. Pharmacol, vol.203, pp.257-263, 2005.

F. C. Fischer, L. Henneberger, M. König, K. Bittermann, L. Linden et al., Modeling exposure in the Tox21 in vitro bioassays, Chem. Res. Toxicol, vol.30, pp.1197-1208, 2017.

R. E. Fitzgerald and M. F. Wilks, Bisphenol A-why an adverse outcome pathway framework needs to be applied, Toxicol. Lett, vol.230, pp.368-374, 2014.

K. Fujita, Y. Masuo, E. Yamazaki, T. Shibutani, Y. Kubota et al., Involvement of the transporters P-glycoprotein and breast cancer resistance protein in dermal distribution of the multikinase inhibitor regorafenib and its active metabolites, J. Pharm. Sci, vol.106, pp.2632-2641, 2017.

R. Fujiwara, S. Takenaka, M. Hashimoto, T. Narawa, and T. Itoh, Expression of human solute carrier family transporters in skin: possible contributor to drug-induced skin disorders, Sci. Rep, vol.4, pp.1-8, 2014.

K. M. Giacomini, S. Huang, D. J. Tweedie, L. Z. Benet, K. L. Brouwer et al., Membrane transporters in drug development, Nat. Rev. Drug Discov, vol.9, pp.215-236, 2010.

D. V. Giacone, V. F. Carvalho, S. K. Costa, and L. B. Lopes, Evidence that P-glycoprotein inhibitor (Elacridar)-loaded nanocarriers improve epidermal targeting of an anticancer drug via absorptive cutaneous transporters inhibition, J. Pharm. Sci, vol.107, pp.698-705, 2018.

P. Godoy, N. J. Hewitt, U. Albrecht, M. E. Andersen, N. Ansari et al., Recent advances in 2D and 3D in vitro systems using primary hepatocytes, cell signaling and ADME. Arch. Toxicol, 2013.
URL : https://hal.archives-ouvertes.fr/hal-00939009

S. Gordon, M. Daneshian, J. Bouwstra, F. Caloni, S. Constant et al., Non-animal models of epithelial barriers (skin, intestine and lung) in research, industrial applications and regulatory toxicology, ALTEX, vol.32, pp.327-378, 2015.

M. Grube, K. Köck, S. Oswald, K. Draber, K. Meissner et al., Organic anion transporting polypeptide 2B1 is a high-affinity transporter for atorvastatin and is expressed in the human heart, Clin. Pharmacol. Ther, vol.80, pp.607-620, 2006.

A. J. Guseman, K. Miller, G. Kunkle, G. P. Dively, J. S. Pettis et al., Multi-drug resistance transporters and a mechanism-based strategy for assessing risks of pesticide combinations to honey bees, PLoS One, 2016.

K. Hacker, R. Maas, J. Kornhuber, M. F. Fromm, and O. Zolk, Substrate-dependent inhibition of the human organic cation transporter OCT2: a comparison of metformin with experimental substrates, PLoS One, vol.10, pp.1-16, 2015.

M. D. Harwood, S. Neuhoff, G. L. Carlson, G. Warhurst, and A. Rostami-hodjegan, Absolute abundance and function of intestinal drug transporters: a prerequisite for fully mechanistic in vitro-in vivo extrapolation of oral drug absorption M, Biopharm. Drug Dispos, vol.34, pp.2-28, 2012.

N. Hashimoto, N. Nakamichi, S. Uwafuji, K. Yoshida, T. Sugiura et al., ATP binding cassette transporters in two distinct compartments of the skin contribute to transdermal absorption of a typical substrate, J. Control. Release, vol.165, pp.54-61, 2013.

N. Hashimoto, N. Nakamichi, E. Yamazaki, M. Oikawa, Y. Masuo et al., P-glycoprotein in skin contributes to transdermal absorption of topical corticosteroids, Int. J. Pharm, vol.521, pp.365-373, 2017.

D. J. Hawthorne and G. P. Dively, Killing them with kindness? In-hive medications may inhibit xenobiotic efflux transporters and endanger honey bees, PLoS One, vol.6, 2011.

K. M. Hillgren, D. Keppler, Z. Arik, K. M. Giacomini, B. Stieger et al., Emerging transporters of clinical importance: an update from the international transporter consortium, Clin. Pharmacol. Ther, vol.94, pp.52-63, 2013.

S. M. Huang and J. Woodcock, Transporters in drug development: advancing on the critical path, Nat. Rev. Drug Discov, vol.9, pp.175-176, 2010.

K. Ito, H. T. Nguyen, Y. Kato, T. Wakayama, Y. Kubo et al., Pglycoprotein (Abcb1) is involved in absorptive drug transport in skin, J. Control. Release, vol.131, pp.198-204, 2008.

S. Jenkinson, G. Chung, E. Van-loon, N. Bakar, A. Dalzell et al., The limitations of renal epithelial cell line HK-2 as a model of drug transporter expression and function in the proximal tubule, Pflugers Arch, vol.464, pp.601-611, 2012.

X. Jiang, F. J. Gonzalez, and A. Yu, Drug-metabolizing enzyme. transporter and nuclear receptor genetically modified mouse models, Drug Metab. Rev, vol.43, pp.27-40, 2011.

E. Jigorel, M. L. Vee, C. Boursier-neyret, Y. Parmentier, and O. Fardel, Differential regulation of sinusoidal and canalicular hepatic drug transporter expression by xenobiotics activating drug-sensing receptors in primary human hepatocytes, Drug Metab. Dispos, vol.34, pp.1756-1763, 2006.
URL : https://hal.archives-ouvertes.fr/hal-00699523

J. W. Jonker, G. Merino, S. Musters, A. E. Van-herwaarden, E. Bolscher et al., The breast cancer resistance protein BCRP (ABCG2) concentrates drugs and carcinogenic xenotoxins into milk, Nat. Med, vol.11, pp.127-129, 2005.

R. Juliano and V. Ling, A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants, Biochim. Biophys. Acta, vol.455, pp.152-162, 1976.

J. C. Kalvass, J. W. Polli, D. L. Bourdet, B. Feng, S. M. Huang et al., Why clinical modulation of efflux transport at the human blood-brain barrier is unlikely: the ITC evidence-based position, Clin. Pharmacol. Ther, vol.94, pp.80-94, 2013.

S. Kim, K. Toshimoto, Y. Yao, T. Yoshikado, and Y. Sugiyama, Quantitative analysis of complex drug-drug interactions between repaglinide and cyclosporin a/ gemfibrozil using physiologically based pharmacokinetic models with in vitro transporter/enzyme inhibition data, J. Pharm. Sci, vol.106, pp.2715-2726, 2017.

C. D. Klaassen and L. M. Aleksunes, Xenobiotic, bile acid, and cholesterol transporters: function and regulation, Pharmacol. Rev, vol.62, pp.1-96, 2010.

C. D. Klaassen and H. Lu, Xenobiotic transporters: ascribing function from gene knockout and mutation studies, Toxicol. Sci, vol.101, pp.186-196, 2008.

D. M. Klein and N. J. Cherrington, Organic and inorganic transporters of the testis: a review, 2014.

V. Kumar, B. Prasad, G. Patilea, A. Gupta, L. Salphati et al., Quantitative transporter proteomics by liquid chromatography with tandem mass spectrometry: addressing methodologic issues of plasma membrane isolation and expression-activity relationship, Drug Metab. Dispo, vol.43, pp.284-288, 2015.

M. Kummu, E. Sieppi, J. Koponen, L. Laatio, K. Vähäkangas et al., Organic anion transporter 4 (OAT 4) modifies placental transfer of perfluorinated alkyl acids PFOS and PFOA in human placental ex vivo perfusion system, Placenta, vol.36, pp.1185-1191, 2015.

L. Merrill, M. Emond, C. Kim, M. J. Antignac, J. Le-bizec et al., Toxicological function of adipose tissue: focus on persistent organic pollutants, Environ. Health Perspect, vol.121, pp.162-169, 2013.
URL : https://hal.archives-ouvertes.fr/hal-01549161

C. L. Lanning, Chlorpyrifos oxon interacts with the mammalian multidrug resistance protein. P-gp, J. Toxicol. Environ. Health, vol.47, pp.395-407, 1996.

L. Vee, M. Jouan, E. Stieger, B. Lecureur, V. Fardel et al., Regulation of human hepatic drug transporter activity and expression by diesel exhaust particle extract, PLoS One, vol.10, 2015.
URL : https://hal.archives-ouvertes.fr/hal-01138535

J. Lee and R. M. Pelis, Drug transport by the blood-aqueous humor barrier of the eye, Drug Metab. Dispos, vol.44, pp.1675-1681, 2016.

G. Lemaire, G. De-sousa, and R. Rahmani, A PXR reporter gene assay in a stable cell culture system: CYP3A4 and CYP2B6 induction by pesticides, Biochem. Pharmacol, vol.68, pp.2347-2358, 2004.

E. M. Leslie, R. G. Deeley, and S. P. Cole, Multidrug resistance proteins: role of Pglycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense, Toxicol. Appl. Pharmacol, vol.204, pp.216-237, 2005.

M. Lohitnavy, Y. Lu, O. Lohitnavy, L. S. Chubb, S. Hirono et al., A possible role of multidrug resistance -associated protein 2 (Mrp2) in hepatic excretion of PCB126, an environmental contaminant: PBPK/PD modeling, Toxicol. Sci, vol.104, pp.27-39, 2008.

W. Löscher and H. Potschka, Role of drug efflux transporters in the brain for drug disposition and treatment of brain diseases, Prog. Neurobiol, vol.76, pp.22-76, 2005.

H. Lu, S. Choudhuri, K. Ogura, L. Csanaky, X. Lei et al., Characterization of organic anion transporting polypeptide 1b2-null mice: essential role in hepatic uptake/toxicity of phalloidin and mycrocystin-LR, Toxicol. Sci, vol.103, pp.35-45, 2008.

T. Luckenbach, S. Fischer, and A. Sturm, Current advances on ABC drug transporters in fish, Comp. Biochem. Physiol. Part C, vol.165, pp.28-52, 2014.

P. Lundquist, J. Lööf, U. Fagerholm, I. Sjögren, J. Johansson et al., Prediction of in vivo rat biliary drug clearance from an in vitro hepatocyte efflux model, Drug Metab. Dispos, vol.42, pp.459-468, 2014.

K. Maeda and Y. Sugiyama, Impact of genetic polymorphisms of transporters on the pharmacokinetic, pharmacodynamic and toxicological properties of anionic drugs, Drug Metab. Pharmacokinet, vol.23, pp.223-235, 2008.

P. Mallick, Utilizing in vitro transporter data in IVIVE-PBPK: an overview. ADMET DMPK 5, vol.201, 2017.

A. Mayr, G. Klambauer, T. Unterthiner, and S. Hochreiter, Toxicity prediction using deep learning, Front. Environ. Sci, vol.3, pp.1-15, 2016.

C. S. Mazur, S. A. Marchitti, and J. Zastre, P-glycoprotein inhibition by the agricultural pesticide propiconazole and its hydroxylated metabolites: implications for pesticidedrug interactions, Toxicol. Lett, vol.232, pp.37-45, 2015.

F. Meier-abt, H. Faulstich, and B. Hagenbuch, Identification of phalloidin uptake systems of rat and human liver, Biochim. Biophys. Acta Biomembr, vol.1664, pp.64-69, 2004.

K. Ménochet, K. E. Kenworthy, J. B. Houston, and A. Galetin, Use of mechanistic modeling to assess interindividual variability and interspecies differences in active uptake in human and rat hepatocytes, Drug Metab. Dispo, vol.40, pp.1744-1756, 2012.

, Japanese Ministry of Health, Labour and Welfare. (Drug interaction guideline for drug development and labeling recommendations), 2014.

J. M. Moreno-navarrete, F. J. Ortega, J. I. Rodriguez-hermosa, M. Sabater, G. Pardo et al., OCT1 expression in adipocytes could contribute to increased metformin action in obese subjects, Diabetes, vol.60, pp.168-176, 2011.

J. Müller, M. Keiser, M. Drozdzik, and S. Oswald, Expression, regulation and function of intestinal drug transporters: an update, Biol. Chem, vol.398, pp.175-192, 2016.

P. Myllynen, M. Kummu, T. Kangas, M. Ilves, E. Immonen et al., ABCG2/BCRP decreases the transfer of a food-born chemical carcinogen, 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) in perfused term human placenta, Toxicol. Appl. Pharmacol, vol.232, pp.210-217, 2008.

M. Nakano, C. Lockhart, E. Kelly, and A. Rettie, Ocular cytochrome P450s and transporters: roles in disease and endobiotic and xenobiotic disposition, Drug Metab. Rev, vol.46, pp.247-260, 2014.

S. Narayan, J. Sinsheimer, K. Paul, Z. Liew, M. Cockburn et al., Genetic variability in ABCB1, occupational pesticide exposure, and Parkinson's disease, Environ. Res, vol.143, pp.98-106, 2015.

S. C. Nicklisch, S. D. Rees, A. P. Mcgrath, T. Gökirmak, L. T. Bonito et al., Global marine pollutants inhibit P-glycoprotein: environmental levels, inhibitory effects, and cocrystal structure, Sci. Adv, vol.2, pp.1-11, 2016.

T. T. Nieskens, J. G. Peters, D. Dabaghie, D. Korte, K. Jansen et al., Expression of organic anion transporter 1 or 3 in human kidney proximal tubule cells reduces cisplatin sensitivity, Drug Metab. Dispos, vol.46, pp.592-599, 2018.

Y. Nozaki, H. Kusuhara, T. Kondo, M. Hasegawa, Y. Shiroyanagi et al., Characterization of the uptake of organic anion transporter (OAT) 1 and OAT3 substrates by human kidney slices, J. Pharmacol. Exp. Ther, vol.321, pp.362-369, 2007.

, User's handbook supplement to the guidance document for developing and assessing AOPs, p.10, 2007.

B. Oosterhuis, K. Vukman, E. Vági, H. Glavinas, I. Jablonkai et al., Specific interactions of chloroacetanilide herbicides with human ABC transporter proteins, Toxicology, vol.248, pp.45-51, 2008.

H. Osman-ponchet, A. Boulai, M. Kouidhi, K. Sevin, M. Alriquet et al., Characterization of ABC transporters in human skin, Drug Metabol. Drug Interact, vol.29, pp.91-100, 2014.

H. Osman-ponchet, A. Gaborit, J. Linget, and C. E. Wilson, Expression of drug transporters in the human skin: comparison in different species and models and its implication for drug development, ADMET DMPK, vol.5, pp.75-84, 2017.

A. Paini, E. Joossens, J. Bessems, A. Desalegn, J. Dorne et al., EURL ECVAM Workshop on New Generation of Physiologically-Based Kinetic Models in Risk Assessment, 2017.

A. Paini, J. A. Leonard, T. Kliment, Y. M. Tan, and A. Worth, Investigating the state of physiologically based kinetic modelling practices and challenges associated with gaining regulatory acceptance of model applications, Regul. Toxicol. Pharmacol, vol.90, pp.104-115, 2017.

A. Paini, J. A. Leonard, E. Joossens, J. G. Bessems, A. Desalegn et al., Next generation physiologically based kinetic (NG-PBK) models in support of regulatory decision making, Comput. Toxicol, vol.9, pp.61-72, 2019.

I. K. Pajeva, C. Globisch, and M. W. , Combined pharmacophore modeling, docking, and 3D QSAR studies of ABCB1 and ABCC1 transporter inhibitors, Chem Med Chem, vol.4, pp.1883-1896, 2009.

Y. Pan, V. Hsu, M. Grimstein, L. Zhang, V. Arya et al., The application of physiologically based pharmacokinetic modeling to predict the role of drug transporters: scientific and regulatory perspectives, J. Clin. Pharmacol, vol.56, pp.122-131, 2016.

A. J. Parker and J. B. Houston, Rate-limiting steps in hepatic drug clearance: comparison of hepatocellular uptake and metabolism with microsomal metabolism of saquinavir, nelfinavir, and ritonavir, Drug Metab. Dispos, vol.36, pp.1375-1384, 2008.

P. Pavek, G. Merino, E. Wagenaar, E. Bolscher, M. Novotna et al., Human breast cancer resistance protein: interactions with steroid drugs, hormones, the dietary carcinogen 2-amino-1-methyl-6-phenylimidazo (4, 5-b) pyridine, and transport of cimetidine, J. Pharmacol. Exp. Ther, vol.312, pp.144-152, 2005.

J. W. Polli, K. L. Olson, J. P. Chism, L. John-williams, . St et al., An unexpected synergist role of P-glycoprotein and breast cancer resistance protein on the central nervous system penetration of the tyrosine kinase inhibitor lapatinib, Drug Metab. Dispos, vol.37, pp.439-442, 2009.

P. Prieto, J. Burton, R. Graepel, A. Price, M. Whelan et al., EURL ECVAM Strategy to Replace, Reduce and Refine the Use of Animals in the Assessment of Acute Mammalian Systemic Toxicity, 2014.

S. Ricketts, P. D. Hockings, and J. C. Waterton, Non-invasive imaging in the pharmaceutical industry, Small Anim. Imaging, vol.17, issue.28, 2011.

R. J. Riley, S. A. Foley, P. Barton, M. G. Soars, and B. Williamson, Hepatic drug transporters: the journey so far, Expert Opin. Drug Metab. Toxicol, vol.12, pp.201-216, 2016.

A. Rodrigues, K. Taskar, H. Kusuhara, and Y. Sugiyama, Endogenous probes for drug transporters: balancing vision with reality, Clin. Pharmacol. Ther, vol.103, pp.434-448, 2018.

B. A. Roggenbeck, M. W. Carew, G. J. Charrois, D. N. Douglas, N. M. Kneteman et al., Characterization of arsenic hepatobiliary transport using sandwich-cultured human hepatocytes, Toxicol. Sci, vol.145, pp.307-320, 2015.

A. Sakamoto, T. Matsumaru, N. Yamamura, Y. Uchida, M. Tachikawa et al., Quantitative expression of human drug transporter proteins in lung tissues: analysis of regional, gender, and interindividual differences by liquid chromatography-tandem mass spectrometry, J. Pharm. Sci, vol.102, pp.3395-3406, 2013.

K. Sayyed, C. Camillerapp, M. Le-vée, A. Bruyère, A. T. Nies et al., Inhibition of organic cation transporter (OCT) activities by carcinogenic heterocyclic aromatic amines, Toxicol. Vitr, vol.54, pp.10-22, 2019.
URL : https://hal.archives-ouvertes.fr/hal-01903262

A. Sedykh, D. Fourches, J. Duan, O. Hucke, M. Garneau et al., Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions, Pharm. Res, vol.30, pp.996-1007, 2013.

A. Seidel, A. Lampen, and B. Ebert, Identification of BCRP as transporter of benzo[a] pyrene conjugates metabolically formed in Caco-2 cells and its induction by Ah-receptor agonists, Carcinogenesis, vol.26, pp.1754-1763, 2005.

H. Shen, D. M. Nelson, R. V. Oliveira, Y. Zhang, C. A. Mcnaney et al., Discovery and validation of pyridoxic acid and homovanillic acid as novel endogenous plasma biomarkers of organic anion transporter (OAT) 1 and OAT3 in Cynomolgus monkeys, Drug Metab. Dispos, vol.46, pp.178-188, 2017.

H. Shen, L. Christopher, Y. Lai, J. Gong, H. Kandoussi et al., Further studies to support the use of coproporphyrin I and III as novel clinical biomarkers for evaluating the potential for organic anion transporting polypeptide 1B1 and OATP1B3 inhibition, Drug Metab. Dispos, vol.46, pp.1075-1082, 2018.

S. Shi and Y. Li, Interplay of drug-metabolizing enzymes and transporters in drug absorption and disposition, Curr. Drug Metab, vol.15, pp.915-941, 2014.

E. Sieppi, K. Vähäkangas, A. Rautio, F. Ietta, L. Paulesu et al., The xenoestrogens, bisphenol A and para-nonylphenol, decrease the expression of the ABCG2 transporter protein in human term placental explant cultures, ADMET DMPK, vol.5, pp.201-211, 2017.

R. Silva, H. Carmo, V. Vilas-boas, D. J. Barbosa, M. Monteiro et al., Several transport systems contribute to the intestinal uptake of Paraquat, modulating its cytotoxic effects, Toxicol. Lett, vol.232, pp.271-283, 2015.

M. G. Soars, K. Grime, J. L. Sproston, P. J. Webborn, and R. J. Riley, Use of hepatocytes to assess the contribution of hepatic uptake to clearance in vivo, Drug Metab. Dispos, vol.35, pp.859-865, 2007.

J. T. Speidel, M. Xu, and S. Z. Abdel-rahman, Bisphenol A (BPA) and bisphenol S (BPS) alter the promoter activity of the ABCB1 gene encoding P-glycoprotein in the human placenta in a haplotype-dependent manner, Toxicol. Appl. Pharmacol, vol.359, pp.47-54, 2018.

B. Stieger and B. Gao, Drug Transporters in the Central Nervous System, 2015.

K. Tachampa, M. Takeda, S. Khamdang, R. Noshiro-kofuji, M. Tsuda et al., Interactions of organic anion transporters and organic cation transporters with mycotoxins, J. Pharm. Sci, vol.106, pp.435-443, 2008.

A. Takeuchi, S. Masuda, H. Saito, T. Abe, and K. Inui, Multispecific substrate recognition of kidney-specific organic anion transporters OAT-K1 and OAT-K2, J. Pharmacol. Exp. Ther, vol.299, pp.261-267, 2001.

R. Thomas, The US Federal Tox21 Program: a strategic and operational plan for continued leadership, ALTEX, vol.35, pp.163-168, 2018.

H. Y. Tiong, P. Huang, S. Xiong, Y. Li, A. Vathsala et al., Drug-induced nephrotoxicity: clinical impact and preclinical in vitro models, Mol. Pharm, vol.11, 2014.

M. Tomi and K. Hosoya, The role of blood-ocular barrier transporters in retinal drug disposition: an overview, Expert Opin. Drug Metab. Toxicol, vol.6, pp.1111-1124, 2010.

A. M. Torres, A. V. Dnyanmote, K. T. Bush, W. Wu, and S. K. Nigam, Deletion of multispecific organic anion transporter Oat1/Slc22a6 protects against mercury-induced kidney injury, J. Biol. Chem, vol.286, pp.26391-26395, 2011.

T. E. Tribull, R. H. Bruner, and L. J. Bain, The multidrug resistance-associated protein 1 transports methoxychlor and protects the seminiferous epithelium from injury, Toxicol. Lett, vol.142, pp.61-70, 2003.

K. Tsaioun, B. J. Blaauboer, and T. Hartung, Evidence-based absorption, distribution, metabolism, excretion (ADME) and its interplay with alternative toxicity methods, ALTEX, vol.33, pp.343-358, 2016.

L. Turco, T. Catone, F. Caloni, E. Di-consiglio, E. Testai et al., Caco-2/ TC7 cell line characterization for intestinal absorption: how reliable is this in vitro model for the prediction of the oral dose fraction absorbed in human?, Toxicol. Vitr, vol.25, pp.13-20, 2011.

K. Vähäkangas and P. Myllynen, Drug transporters in the human blood-placental barrier, Br. J. Pharmacol, vol.158, pp.665-678, 2009.

A. E. Van-herwaarden and A. H. Schinkel, The function of breast cancer resistance protein in epithelial barriers, stem cells and milk secretion of drugs and xenotoxins, Trends Pharmacol. Sci, vol.27, pp.10-16, 2006.

M. V. Varma, S. J. Steyn, C. Allerton, and A. F. El-kattan, Predicting clearance mechanism in drug discovery: extended clearance classification system (ECCS), Pharm. Res, vol.32, pp.3785-3802, 2015.

T. Vasconcelos, S. Marques, and B. Sarmento, The biopharmaceutical classification system of excipients, Ther. Deliv, vol.8, pp.65-78, 2017.

L. Vernhet, A. Courtois, N. Allain, L. Payen, J. P. Anger et al., Overexpression of the multidrug resistance-associated protein (MRP1) in human heavy metal-selected tumor cells, FEBS Lett, vol.443, pp.1716-1721, 1999.

D. L. Villeneuve, D. Crump, N. Garcia-reyero, M. Hecker, T. H. Hutchinson et al., Adverse outcome pathway (AOP) development I: strategies and principles, Toxicol. Sci, vol.142, pp.312-320, 2014.

M. Vinken, The adverse outcome pathway concept: a pragmatic tool in toxicology, Toxicology, vol.312, pp.158-165, 2013.

M. L. Vlaming, S. F. Teunissen, E. Steeg, . Van-de, A. Esch et al., Bcrp1; Mdr1a/b; Mrp2 combination knockout mice: altered disposition of the dietary carcinogen PhIP (2-amino-1-methyl-6-phenylimidazo [4, 5-b] pyridine) and its genotoxic metabolites, Mol. Pharmacol, vol.85, pp.520-530, 2014.

D. A. Volpe, Transporter assays as useful in vitro tools in drug discovery and development, Expert Opin. Drug Discov, vol.11, pp.91-103, 2016.

M. A. Welch, K. Kock, T. J. Urban, K. L. Brouwer, and P. W. Swaan, Toward predicting drug-induced liver injury: parallel computational approaches to identify multidrug resistance protein 4 and bile salt export pump inhibitors, 2015.

. Dispos, , vol.43, pp.725-734

X. Wen, C. J. Gibson, I. Yang, B. Buckley, M. J. Goedken et al., MDR1 transporter protects against paraquat-induced toxicity in human and mouse proximal tubule cells, Toxicol. Sci, vol.141, pp.475-483, 2014.

M. F. Wilks and A. M. Tsatsakis, Environmental contaminants and target organ toxicities -new insights into old problems, Toxicol. Lett, vol.230, pp.81-84, 2014.

C. Wittwehr, H. Aladjov, G. Ankley, H. J. Byrne, J. De-knecht et al., How adverse outcome pathways can aid the development and use of computational prediction models for regulatory toxicology, Toxicol. Sci, vol.155, pp.326-336, 2017.

R. R. Worley and J. Fisher, Application of physiologically-based pharmacokinetic modeling to explore the role of kidney transporters in renal reabsorption of perfluorooctanoic acid in the rat, Toxicol. Appl. Pharmacol, vol.289, pp.428-441, 2015.

C. Wu and L. Z. Benet, Predicting drug disposition via application of BCS: transport/ absorption/elimination interplay and development of a biopharmaceutics drug disposition classification system, Pharm. Res, vol.22, pp.11-23, 2005.

D. Xu and G. You, Loops and layers of post-translational modifications of drug transporters, Adv. Drug Deliv. Rev, vol.116, pp.37-44, 2017.

C. H. Yang, K. P. Glover, and X. Han, Characterization of cellular uptake of perfluorooctanoate via organic anion-transporting polypeptide 1A2, organic anion transporter 4, and urate transporter 1 for their potential roles in mediating human renal reabsorption of perfluorocarboxylates, Toxicol. Sci, vol.117, pp.294-302, 2010.

S. W. Yee, M. M. Giacomini, C. H. Hsueh, D. Weitz, X. Liang et al., Metabolomic and genome-wide association studies reveal potential endogenous biomarkers for OATP1B1, Clin. Pharmacol. Ther, vol.100, pp.524-536, 2016.

M. Yoon, A. Efremenko, B. J. Blaauboer, and H. J. Clewell, Evaluation of simple in vitro to in vivo extrapolation approaches for environmental compounds, Toxicol. Vitr, vol.28, pp.164-170, 2014.

H. You, K. Lee, S. Lee, S. B. Hwang, K. Kim et al., Computational classification models for predicting the interaction of compounds with hepatic organic ion importers, Drug Metab. Pharmacokinet, vol.30, pp.347-351, 2015.

J. Yu, Z. Zhou, J. Tay-sontheimer, R. H. Levy, and I. Ragueneau-majlessi, Risk of clinically relevant pharmacokinetic-based drug-drug interactions with drugs approved by the U.S. Food and Drug Administration between, Drug Metab. Dispos, vol.46, pp.835-845, 2013.

J. M. Zaldivar-comenges, E. Joossens, J. V. Benito, A. Worth, and A. Paini, Theoretical and mathematical foundation of the virtual cell based assay -a review, Toxicol. Vitr, vol.45, pp.209-221, 2017.

M. Zamek-gliszczynski, C. Lee, A. Poirier, J. Bentz, X. Chu et al., ITC recommendations for transporter kinetic parameter estimation and translational modeling of transport-mediated PK and DDIs in humans, Clin. Pharmacol. Ther, vol.94, pp.64-79, 2013.

M. Zamek-gliszczynski, M. Taub, P. Chothe, X. Chu, K. Giacomini et al., Transporters in drug development: 2018 ITC recommendations for transporters of emerging clinical importance, Clin. Pharmacol. Ther, vol.104, pp.890-899, 2018.

J. Zastre, C. Dowd, J. Bruckner, and A. Popovici, Lack of P-glycoprotein-mediated efflux and the potential involvement of an influx transport process contributing to the intestinal uptake of deltamethrin, cis-permethrin, and trans-permethrin, Toxicol. Sci, vol.136, pp.284-293, 2013.

Z. Zhang and J. D. Unadkat, Development of a novel maternal-fetal physiologically based pharmacokinetic model II: verification of the model for passive placental permeability drugs, Drug Metab. Dispos, vol.45, pp.939-946, 2017.

Z. Zhang, M. Z. Imperial, G. I. Patilea-vrana, J. Wedagedera, L. Gaohua et al., Development of a novel maternal-fetal physiologically based pharmacokinetic model I: insights into factors that determine fetal drug exposure through simulations and sensitivity analyses, Drug Metab. Dispos, vol.45, pp.920-938, 2017.

W. Zhao, J. D. Zitzow, Y. Weaver, D. J. Ehresman, S. Chang et al., Organic anion transporting polypeptides contribute to the disposition of perfluoroalkyl acids in humans and rats, Toxicol. Sci, vol.156, pp.84-95, 2017.